Summary A study was made of the incidence of p53 mutations in Japanese males with prostate cancer or benign prostatic hyperplasia. Polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) was used as a primary screening technique with gene sequencing being carried out in positive cases. Two out of 21 prostate cancers (9.5%) were found to have p53 mutations. These were stage B2 and D2 prostate cancers. No abnormalities were found in the remaining cases or benign prostatic hyperplasia.
Summary A study was made of the incidence of p53 mutations in Japanese males with prostate cancer or benign prostatic hyperplasia. Polymerase chain reaction single-strand conformation polymorphism (PCR-SSCP) was used as a primary screening technique with gene sequencing being carried out in positive cases. Two out of 21 prostate cancers (9.5%) were found to have p53 mutations. These were stage B2 and D2 prostate cancers. No abnormalities were found in the remaining cases or benign prostatic hyperplasia.
Mutations of the p53 gene would thus appear infrequent in the tumourigenesis of primary prostate cancer.
Prostatic adenocarcinoma is the fourth and second most common cause of cancer death among men in the UK (Davies & Eaton, 1991) and United States (Silverberg et al., 1990) (Waterhouse et al., 1982) . Recent advances in molecular genetics of other prevalent tumours, such as colorectal (Vogelstein et al., 1988) , bladder (Tsai et al., 1990) , lung and breast cancers (Callahan & Cambell, 1989) , indicate multiple genetic alterations by activation of oncogenes (see Bishop, 1991 for reviews) and, more importantly, the inactivation of tumour suppressor genes (see Marshall, 1991 (Carter et al., 1990c (Kaighn et al., 1979) and DU-145 (Stone et al., 1978) , were obtained from the American Tissue Type Collection and used as positive controls. In PC-3, a C deletion at codon 138 on exon 5 of the p53 gene and a point mutation at codon 223 on exon 6 and codon 274 on exon 8 in DU-145 have been reported by Isaacs et al. (1991) . The human lung cancer cell line, KTA-7 (Kasai et al., 1991) , was cultured in serum free medium, ACL-3, and had a point mutation on exon 5 of the p53 gene (Wada et (Herrmann & Frishhauf, 1987 (Hsu et al., 1991) . The designations and sequence in each primer are as follows: PX5LT,TGTTCACTTGTGCCCTGACT  PX6LT,TGGTTGCCCAGGGTCCCCAG   PX7LT,C-1GCCACAGGTCTCCCCAA   PX8LT,TTGGGAGTAGATGGAGCCT  SX5LT,TTCAACTCTGTCTCCTrCCT  SX6LT,GCCTCTGATTCCTCACTGA  SX7LT,AGGCGCACTGGCCTCATCAA   SX8LT,TTCCTTACTGCCTCTTGCF   PX5RT,CAGCCCTGTCGTCTCTCCAG  PX6RT,GGAGGGCCACTGACAACCA  PX7RT,AGGGGTCAGCGGCAAGCAGA  PX8RT,AGTGTTAGACTGGAAAC1-TT  SX5RT,CAGCCCTGTCGTCTCTCCAG  SX6RT,TAACCCCTCCTCCCAGAGA  SX7RT,TGTGCAGGGTGGCAAGTGGC  SX8RT 
The number in each designation indicates the region of the exon of the p53 gene examined by PCR-SSCP analysis. 'LT' and 'RT' indicate primers upstream and downstream, respectively, in each region and 'PX' and 'SX', the PCR and sequence primers.
PCR-SSCP Point mutations in the p53 gene were detected by a modified version of PCR-SSCP method . Briefly, the 5'-ends of primers (100 pmol (Figure 3a) . A point mutation also occurred in case 246 at codon 280. Instead of the wild type sequence AGA, the sequence ACA was observed. This causes a change in amino acid from wild type arginine to threonine ( Figure  3b ). In both cases with wild type sequence was also detected, which suggests that only one allele was affected. However, the presence of wild type might be due to normal cells such as fibroblasts within the tumour sample.
Discussion
Prostatic adenocarcinoma is one of the most prevalent cancers in men. Approximately 4,000 and 28,000 men die each year in the UK (Davies & Eaton, 1991) and the United States (Carter & Coffey, 1990) , respectively. It is now the fourth and second leading cause of cancer death among men in both of these countries. Because of the rapid increase in morbidity and mortality, prostate cancer has become a significant medical problem also in Japan. (Jap. Health Welfare Statistics Associ. 1991). However, there is still a wide geographic and racial differences in the incidence of clinically diagnosed prostate cancer up to ten times between the United States and Japan (Yatani et al., 1989) . The combined effects of race and diet may possibly serve as a basis for predicting some, but not all the epidemiological spectrum of a prostate cancer (Carter et al., 1990b; Carter et al., 1992d; Anwar et al., 1992) .
The molecular mechanisms involved in prostate tumourigenesis remain virtually unclarified. Various abnormalities have been reported in the molecular genetics of prostate cancer, such as overexpression of growth factors that include the fibroblast growth factor, transforming growth factor-1B families, transforming growth factor-o and epidermal growth factor (Davies & Eaton, 1991; see Thompson, 1990 for review). Elevated activities of proto-oncogenes such as ras and myc has also been detected in prostate cancer L. Eaton, 1991; see Thompson, 1990 for reviews). Mutations of the ras oncogene are also present (Carter et al., 1 990a ; Anwar et al., 1992) . The myc oncogene alone has been found to cause hyperplastic change in prostatic epithelium, whereas the ras + myc condition has been observed to induce predominantly malignant carcinomas in the mouse prostate reconstitution model (Thompson et al., 1989) . Recent studies highlight the possible role of tumour suppressor genes in the pathogenesis of various malignant tumours (see Marshall, 1991 for reviews). Inactivation of tumour suppressor genes by the deletion of one copy of the gene and mutational inactivation of the other can lead to uncontrollable cellular proliferation characteristic of cancer. The retinoblastoma gene (Cavenee et al., 1983; Bookstein et al., 1990 ), Wilms's tumour gene (Gessler et al., 1990) , DCC gene (Fearon et al., 1990) , neurofibromatosis I gene (Wallace et al., 1990) , and p53 gene on chromosome 17p ) are among known tumour suppressor genes. Cytogenetic analysis of prostate cancer has yet to consistently show chromosomal deletions. A study of these chromosomes indicated highest frequency of allelic deletions resides on chromsome 8p (Bergerheim et al., 1991) , followed by lOq (Atkin & Baker, 1985; Brothman et al., 1990; Carter et al., 1991c; Bergerheim et al., 1991) and 16q (Carter et al., 1991c; Bergerheim 3et al., 1991) . The frequent loss of heterozygosity at loci on chromosome 17p, where the tumour suppressor gene p53 is located, has been shown in a wide variety of human tumours including those of colon, lung, breast, ovary and bladder (see Hollstein et al., 1991 for reviews; see Levine et al., 1991 for reviews). In previous studies on primary prostate cancer, allelic loss of chromosome 17p was noted in about one-fifth of tumours, suggesting inactivation of the p53 gene to be importantly involved in human prostatic carcinogenesis (Carter et al., 1990c) . The p53 gene was initially identified by its ability to bind the large T antigen of the DNA virus, SV40 (Lane & Crawford, 1979) . It is considered to be essential to the regulation of cell proliferation (Boyd & Barrett, 1990) . Transfection studies indicate the wild type protein is to be capable of suppressing cell proliferation and transformation (Finlay et al., 1989; Mercer et al., 1990) . Most mutations of this gene found in a variety of surgical specimens from malignant tumours are clustered in the highly conserved region between amino-acid residues 130 and 290 see Levine et al., 1991 for reviews (Isaccs et al., 1991) . In another report, a T to C alteration at codon 172 was a feature of both the primary and metastatic tumours common to the regional node (Effert et al., 1991) . Significant difference in the immunoreactivity of the monoclonal antibody toward the p53 gene product has been observed for prostate cancer and benign prostatic hyperplasia. Five of the 29 (17%) prostate cancer specimens stained positive, but none in the 34 samples from patients with benign prostatic hyperplasia (Thompson et al., 1992) . In our study, p53 gene mutations were detected in only two of the 21 (9.5%) specimens of prostate cancer. No specimens of benign prostatic hyperplasia possessed a mutation of this gene. The incidence of point mutations of this gene found in our study was (Gannon et al., 1990) . Both samples which exhibited mutant p53 gene in this study also possessed a wild type sequence due possibly to the intact allele in the presence of the affected allele of this gene. Detection of a contaminant such as fibroblasts within the tumour samples is also a possibility. The incidence of p53 gene mutations found in this study is thus probably a minimal estimate. The incidence of mutations in ras families have recently been shown to be higher in Japanese prostate cancers than in American counterparts (Anwar et al., 1992) . It is of interest to note that the observed difference in the incidence of p53 gene mutations might have arisen from a variation in epidemiological factors (Carter et al., 1990b; Anwar et al., 1992) . The incidence of mutations of the p53 gene (exons 5 through 8) has been found to be infrequent in primary prostate cancer in Japan. No case of benign prostatic hyperplasia possessed mutations of this gene. Elucidation of the role of p53 gene mutations in metastasis and the incidence of mutations in exons other than 5 to 8 should be carried out.
